Non-Invasive Screening for Fetal Aneuploidy: A New Maternal Plasma Marker

NCT00770458 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1000

Last updated 2010-01-06

No results posted yet for this study

Summary

Validate that circulating cell free fetal nucleic acid can be used to identify a direct marker for fetal aneuploidy, particularly fetal Down Syndrome (DS), that is better than surrogate markers.

Conditions

  • Down Syndrome (Trisomy 21)
  • Edwards Syndrome (Trisomy 18)
  • Patau Syndrome (Trisomy 13)
  • Turner Syndrome

Sponsors & Collaborators

  • Sequenom, Inc.

    lead INDUSTRY

Principal Investigators

  • Allan Bombard, MD · Sequenom, Inc.

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-06-30
Primary Completion
2009-10-31
Completion
2009-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00770458 on ClinicalTrials.gov